Skip to main content

PharmaCyte Biotech, Inc. (PMCB)

NASDAQ: PMCB · IEX Real-Time Price · USD
3.04 -0.06 (-1.94%)
Oct 15, 2021 4:00 PM EDT - Market closed
Market Cap62.97M
Revenue (ttm)n/a
Net Income (ttm)-3.69M
Shares Out1.59M
EPS (ttm)-2.36
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume344,454
Open3.08
Previous Close3.10
Day's Range3.00 - 3.12
52-Week Range2.25 - 9.98
Beta0.15
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About PMCB

PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other tumors, including encapsulated genetically modified living cell...

IndustryBiotechnology
Founded1996
Employees4
Stock ExchangeNASDAQ
Ticker SymbolPMCB
Full Company Profile

Financial Performance

Financial Statements

News

PharmaCyte Biotech Announces Encapsulation Material Does Not Alter Cellular DNA

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech announces that its encapsulation material does not alter cellular DNA.

2 weeks ago - Business Wire

PharmaCyte Biotech Releases More Positive Results From FDA-Required Biocompatibility Tests

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech releases more positive results from the FDA required biocompatibility tests. The clinical trial capsules passed the t...

3 weeks ago - Business Wire

Why Are PharmaCyte Shares Moving Higher On Thursday?

PharmaCyte Biotech Inc (NASDAQ: PMCB) stock is moving higher in reaction to the first test results of the biocompatibility studies of its CypCaps trial product candidate. These results were from an "In ...

1 month ago - Benzinga

PharmaCyte Biotech Announces Positive Results of Biocompatibility Study for FDA

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #Biotechnology--PharmaCyte Biotech announces positive results of one of the biocompatibility studies required by the FDA.

1 month ago - Business Wire

7 Penny Stocks Waiting on The FDA for Rocket Fuel

News of regulatory approval or progress would really help to move the needle for these seven biotech penny stocks. The post 7 Penny Stocks Waiting on The FDA for Rocket Fuel appeared first on InvestorPl...

1 month ago - InvestorPlace

After Nasdaq Uplisting, PharmaCyte Biotech Looks Ready to Rumble

There's no denying that PMCB stock has lost much of its value over the years. However, recent developments could catalyze a price resurgence.

1 month ago - InvestorPlace

Why Is PharmaCyte Biotech Stock Moving Higher In Premarket Thursday?

The stock price of PharmaCyte Biotech Inc (NASDAQ: PMCB) is trading higher during premarket today.  Investors are expecting a major announcement from the company today.

1 month ago - Benzinga

PharmaCyte Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #AnotherFDARequiedTestPasses--PharmaCyte Biotech participates in the H.C. Wainwright 23rd Annual Global Investment Conference.

1 month ago - Business Wire

PharmaCyte Biotech Establishes 18-Month Shelf Life for Clinical Trial Product in Ongoing Stability Study

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #AnotherFDARequiedTestPasses--PharmaCyte Biotech establishes 18-month shelf life for its clinical trial product to be used in its Phase 2b clinical tria...

1 month ago - Business Wire

PharmaCyte Biotech Expands Product Pipeline to Include Diabetes and Malignant Ascites Following $90-Million Capital R...

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #Ascites--PharmaCyte expands product pipeline to include diabetes and malignant ascites following $90 million in capital raises.

1 month ago - Business Wire

PharmaCyte Biotech Announces Closing of $70 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte closes $70 million offering and explains how these funds will be used to grow the Company into the future and create shareholder value.

1 month ago - Business Wire

PharmaCyte Biotech Announces $70 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #70MillionRaise--PharmaCyte announces $70 million registered direct offering priced At-the-Market under the Nasdaq rules.

1 month ago - Business Wire

PMCB Stock: 14 Things to Know About PharmaCyte Biotech as Shares Skyrocket

PharmaCyte Biotech (PMCB) stock is taking off Wednesday and there are a few things that potential investors need to know about the company. The post PMCB Stock: 14 Things to Know About PharmaCyte Biotec...

1 month ago - InvestorPlace

PharmaCyte Biotech Releases Statement on Nasdaq Uplisting and Current Business Focus

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #BigBoardStock--PharmaCyte releases statement on Nasdaq uplisting and current business focus.

2 months ago - Business Wire

PMCB Stock: 2 Big Reasons PharmaCyte Biotech Is Soaring 70% Today

Today, two key catalysts are taking PMCB stock higher, as investors seem to like the positioning of biotech PharmaCyte. The post PMCB Stock: 2 Big Reasons PharmaCyte Biotech Is Soaring 70% Today appeare...

2 months ago - InvestorPlace

PharmaCyte Biotech Announces Closing of $15-Million Public Offering

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #BigBoardStock--PharmaCyte Biotech announces closing of its public offering of approximately $15 million.

2 months ago - Business Wire

PharmaCyte Biotech Announces Uplist Date to NASDAQ and Pricing of $15 Million Public Offering

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #NASDAQ--PharmaCyte Biotech announces uplist date to NASDAQ and pricing of $15 million public offering.

2 months ago - Business Wire

PharmaCyte Biotech Announces Uplist to The Nasdaq Capital Market and Launch of Public Offering

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $NASDAQ #bigboardstock--PharmaCyte Biotech uplists to Nasdaq and launches a public offering.

2 months ago - Business Wire

PharmaCyte Biotech Provides Update to Nasdaq Listing Efforts and Presents Scientific Publications Supporting Pancreat...

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $PMCB #DrugDiscovery--PharmaCyte provides update to Nasdaq listing efforts and presents scientific publications supporting pancreatic cancer treatment.

2 months ago - Business Wire

PharmaCyte Biotech Announces Update on Study Progress and Uplist to Nasdaq

LAGUNA HILLS, Calif.--(BUSINESS WIRE)---- $Nasdaq #Nasdaq--PharmaCyte Biotech updates shareholders on biocompatibility study progress and its plans to uplist to Nasdaq.

3 months ago - Business Wire